NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- Conditions
- Advanced Esophageal AdenocarcinomaAdvanced Gastric AdenocarcinomaAdvanced Gastroesophageal Junction AdenocarcinomaClinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingOther: Questionnaire Administration
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 224
- Registration Number
- NCT06203600
- Locations
- 🇺🇸
Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont, United States
🇺🇸University of Vermont Medical Center, Burlington, Vermont, United States
🇺🇸University of Vermont and State Agricultural College, Burlington, Vermont, United States
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
- Conditions
- Breast Atypical HyperplasiaBreast CarcinomaBreast Ductal Carcinoma In SituBreast Lobular Carcinoma In Situ
- Interventions
- Procedure: Biospecimen CollectionProcedure: MammographyOther: Questionnaire AdministrationProcedure: Random Periareolar Fine-Needle Aspiration
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT06195306
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸University of Kansas Cancer Center, Kansas City, Kansas, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
- Conditions
- Breast CarcinomaBreast Ductal Carcinoma In SituBreast Lobular Carcinoma In SituEstrogen Receptor-Positive Breast Carcinoma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: MammographyOther: Questionnaire Administration
- First Posted Date
- 2023-12-28
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 200
- Registration Number
- NCT06184750
- Locations
- 🇺🇸
University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of Illinois College of Medicine - Chicago, Chicago, Illinois, United States
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Patient MonitoringProcedure: Positron Emission TomographyProcedure: Skeletal Survey X-Ray
- First Posted Date
- 2023-12-22
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 78
- Registration Number
- NCT06179888
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
- Conditions
- Locally Advanced ChondrosarcomaLocally Advanced Sinonasal AdenocarcinomaMetastatic Olfactory NeuroblastomaLocally Advanced Olfactory NeuroblastomaMetastatic Sinonasal Undifferentiated CarcinomaMetastatic Sinonasal AdenocarcinomaLocally Advanced Large-cell Neuroendocrine CarcinomaMetastatic ChondrosarcomaLocally Advanced Sinonasal Undifferentiated CarcinomaMetastatic Large-cell Neuroendocrine Carcinoma
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT06176989
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Conditions
- Ganglioneuroblastoma, NodularNeuroblastoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: FDG-Positron Emission Tomography and Computed Tomography ScanProcedure: Hematopoietic Cell TransplantationProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanRadiation: Radiation TherapyProcedure: Radionuclide ImagingOther: Survey AdministrationProcedure: Tumor Resection
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 478
- Registration Number
- NCT06172296
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸Banner Children's at Desert, Mesa, Arizona, United States
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT06169215
- Locations
- 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸UCI Health Laguna Hills, Laguna Hills, California, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
Pilot Study of Isocaloric Time Restricted Eating on Ketone Metabolism and Immunoregulation
- Conditions
- Body WeightObesity
- Interventions
- Behavioral: Early Time-Restricted Eating
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 150
- Registration Number
- NCT06169137
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors
- Conditions
- Adult Ovarian Granulosa Cell Tumor
- Interventions
- Procedure: Biospecimen CollectionProcedure: Chest RadiographyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT06169124
- Locations
- 🇺🇸
West Michigan Cancer Center, Kalamazoo, Michigan, United States
🇺🇸Ascension Borgess Cancer Center, Kalamazoo, Michigan, United States
🇺🇸Trinity Health Saint Mary Mercy Livonia Hospital, Livonia, Michigan, United States
Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer
- Conditions
- Stress Urinary IncontinenceUrinary Urge IncontinenceProstatic Hyperplasia
- Interventions
- Device: Elidah Device
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT06161506
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States